Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 53


Activated Carbon-Based System for the Disposal of Psychoactive Medications.

Song Y, Manian M, Fowler W, Korey A, Kumar Banga A.

Pharmaceutics. 2016 Nov 7;8(4). pii: E31.


Counselor training and attitudes toward pharmacotherapies for opioid use disorder.

Aletraris L, Edmond MB, Paino M, Fields D, Roman PM.

Subst Abus. 2016;37(1):47-53. doi: 10.1080/08897077.2015.1062457.


Prior Experience with Non-Prescribed Buprenorphine: Role in Treatment Entry and Retention.

Monico LB, Mitchell SG, Gryczynski J, Schwartz RP, O'Grady KE, Olsen YK, Jaffe JH.

J Subst Abuse Treat. 2015 Oct;57:57-62. doi: 10.1016/j.jsat.2015.04.010.


Comparative trial to study the effectiveness of clonidine hydrochloride and buprenorphine-naloxone in opioid withdrawal - a hospital based study.

Hussain SS, Farhat S, Rather YH, Abbas Z.

J Clin Diagn Res. 2015 Jan;9(1):FC01-4. doi: 10.7860/JCDR/2015/10625.5425.


Buprenorphine maintenance and mu-opioid receptor availability in the treatment of opioid use disorder: implications for clinical use and policy.

Greenwald MK, Comer SD, Fiellin DA.

Drug Alcohol Depend. 2014 Nov 1;144:1-11. doi: 10.1016/j.drugalcdep.2014.07.035. Review.


Utilizing buprenorphine-naloxone to treat illicit and prescription-opioid dependence.

Mauger S, Fraser R, Gill K.

Neuropsychiatr Dis Treat. 2014 Apr 7;10:587-98. doi: 10.2147/NDT.S39692. Review.


Impact of research network participation on the adoption of buprenorphine for substance abuse treatment.

Rieckmann TR, Abraham AJ, Kovas AE, McFarland BH, Roman PM.

Addict Behav. 2014 May;39(5):889-96. doi: 10.1016/j.addbeh.2014.01.016.


Selective review and commentary on emerging pharmacotherapies for opioid addiction.

Ling W, Mooney L, Zhao M, Nielsen S, Torrington M, Miotto K.

Subst Abuse Rehabil. 2011 Oct 28;2:181-8. doi: 10.2147/SAR.S22782. Review.


Psychometric properties of the adjective rating scale for withdrawal across treatment groups, gender, and over time.

Barbosa-Leiker C, McPherson S, Mamey MR, Burns GL, Roll J.

J Subst Abuse Treat. 2014 Feb;46(2):251-6. doi: 10.1016/j.jsat.2013.08.020.


Organizational implementation of evidence-based substance abuse treatment in racial and ethnic minority communities.

Guerrero EG, He A, Kim A, Aarons GA.

Adm Policy Ment Health. 2014 Nov;41(6):737-49. doi: 10.1007/s10488-013-0515-3.


Comparison of behavioral treatment conditions in buprenorphine maintenance.

Ling W, Hillhouse M, Ang A, Jenkins J, Fahey J.

Addiction. 2013 Oct;108(10):1788-98. doi: 10.1111/add.12266.


Establishing the feasibility of measuring performance in use of addiction pharmacotherapy.

Thomas CP, Garnick DW, Horgan CM, Miller K, Harris AH, Rosen MM.

J Subst Abuse Treat. 2013 Jul;45(1):11-8. doi: 10.1016/j.jsat.2013.01.004.


HIV/AIDS and drug use in China--interactions, impacts, and issues.

Zhao M, Ling W.

Subst Use Misuse. 2012 Jun-Jul;47(8-9):1015-25. doi: 10.3109/10826084.2012.663284.


Opioid detoxification and naltrexone induction strategies: recommendations for clinical practice.

Sigmon SC, Bisaga A, Nunes EV, O'Connor PG, Kosten T, Woody G.

Am J Drug Alcohol Abuse. 2012 May;38(3):187-99. doi: 10.3109/00952990.2011.653426. Review.


Illicit use of buprenorphine in a community sample of young adult non-medical users of pharmaceutical opioids.

Daniulaityte R, Falck R, Carlson RG.

Drug Alcohol Depend. 2012 May 1;122(3):201-7. doi: 10.1016/j.drugalcdep.2011.09.029.


Site selection in community-based clinical trials for substance use disorders: strategies for effective site selection.

Potter JS, Donovan DM, Weiss RD, Gardin J, Lindblad R, Wakim P, Dodd D.

Am J Drug Alcohol Abuse. 2011 Sep;37(5):400-7. doi: 10.3109/00952990.2011.596975.


Improving temporal efficiency of outpatient buprenorphine induction.

Gunderson EW, Levin FR, Rombone MM, Vosburg SK, Kleber HD.

Am J Addict. 2011 Sep-Oct;20(5):397-404. doi: 10.1111/j.1521-0391.2011.00153.x.

Supplemental Content

Support Center